Publications by authors named "Wieneke J A van Geel"
We describe a modification of a previously described assay for the quantification of alpha-synuclein in naive cerebrospinal fluid, which allows for a more efficient quantification of alpha-synuclein. Detection limit of the assay is 3.8 ng/ml and the assay is linear until 300 ng/ml.
View Article and Find Full Text PDFBackground: Cerebrospinal fluid (CSF) concentrations of amyloid beta(42) (Abeta(42)) peptides and tau proteins may serve as biomarkers for Alzheimer disease (AD). Recently, the xMAP technology has been introduced as an alternative to ELISA for measurement of these markers.
Methods: We used xMAP assays and ELISA to analyze CSF concentrations of Abeta(42), total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau(181)) in samples from 69 patients with Alzheimer disease, 26 patients with vascular dementia, and 55 controls without neurological disorders.
Background: This study was aimed to develop a sensitive and rapid assay for the determination of glial fibrillary acidic protein (GFAP) in serum and to evaluate the clinical applicability in serum samples from patients with acute stroke.
Methods: The two-site chemiluminometric immunoassay, intended to use in a near-patient setting with a single incubation step (20 min), was used to measure serum samples from healthy blood donors and from patients with brain injury and correlated to serum S100B levels.
Results: The GFAP assay covered a concentration range up to 18 microg/L with an analytical sensitivity of 0.
Background: In the present study, a new assay for the measurement of glial fibrillary acidic protein (GFAP) in human blood is described. The aim of the study was to present the characteristics of a new GFAP assay for blood analysis.
Methods: The method, a newly developed enzyme-linked immunosorbent assay (ELISA), was validated using blood samples from healthy blood donors and from patients with severe traumatic brain injury (TBI).